Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults Elisabetta Patorno, Ajinkya Pawar, Lily G. Bessette, Dae H. Kim, Chintan Dave, Robert J. Glynn, Medha N. Munshi, Sebastian Schneeweiss, Deborah J.
Patients with type 2 diabetes are at high risk of developing renal and cardiovascular complications. Sodium–glucose cotransporter 2 (SGLT2) inhibitors have garnered interest due to their glucose-independent cardiorenal protective effects, as reported in trials including participants with and without diabetes,
AbstractOBJECTIVE | Sodium–glucose cotransporter 2 (SGLT2) inhibitors are approved for type 1 diabetes in Europe and Japan, with off-label use in type 1 diabetes in the United States. Although there were no consistent approaches to risk mitigation in clinical trials
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are second- to third-line antidiabetes drugs that have been shown to have cardiovascular benefits. However, in premarketing trials of the SGLT2 inhibitor dapagliflozin, there were numerical imbalances in breast cancer events compared with placebo; all
AbstractOBJECTIVE To examine the comparative effectiveness of the sodium–glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin and other non-SGLT2i antihyperglycemics on the risk of major adverse kidney events (MAKE) of estimated glomerular filtration rate (eGFR) decline >50%, end-stage kidney disease, or all-cause
More than 10% of adults undergoing colonoscopy have type 2 diabetes (T2D) (1). The use of sodium–glucose cotransporter 2 inhibitors (SGLT2i) has increased due to their glycemic control and benefits of lowering cardiovascular morbidity and mortality as well as reducing
Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study Oriana Hoi Yun Yu, Sophie Dell’Aniello, Baiju R. Shah, Vanessa C. Brunetti, Jean-Marc Daigle, Michael Fralick, Antonios Douros, Nianping Hu, Silvia Alessi-Severini, Anat Fisher, Shawn C.
1.Tancredi, M. et al. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 373, 1720–1732 (2015).CAS PubMed Google Scholar 2.Bommer, C. et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study.
Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics Ele Ferrannini, Ashwin C. Murthy, Yong-ho Lee, Elza Muscelli, Sophie Weiss, Rachel M. Ostroff, Naveed Sattar, Stephen A. Williams, Peter Ganz Diabetes Care Sep 2020, 43 (9) 2183-2189; DOI: 10.2337/dc20-0456
Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in